guanethidine has been researched along with exenatide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brubaker, PL; Gil-Lozano, M; González-Matías, LC; Mallo, F; Outeiriño-Iglesias, V; Romaní-Pérez, M; Vigo, E | 1 |
1 review(s) available for guanethidine and exenatide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for guanethidine and exenatide
| Article | Year |
|---|---|
Corticotropin-releasing hormone and the sympathoadrenal system are major mediators in the effects of peripherally administered exendin-4 on the hypothalamic-pituitary-adrenal axis of male rats.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Animals; Arginine Vasopressin; Cells, Cultured; Corticosterone; Corticotrophs; Corticotropin-Releasing Hormone; Exenatide; Glucagon-Like Peptide 1; Guanethidine; Hypothalamo-Hypophyseal System; Male; Peptide Fragments; Peptides; Pituitary-Adrenal System; Rats; Rats, Sprague-Dawley; Receptors, Corticotropin-Releasing Hormone; Sympathetic Nervous System; Time Factors; Venoms | 2014 |